These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32007507)

  • 41. RETRACTED: Sustained delivery of epalrestat to the retina using PEGylated solid lipid nanoparticles laden contact lens.
    Zhu Y; Sheng Y
    Int J Pharm; 2020 Sep; 587():119688. PubMed ID: 32717281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of surfactant chain length on drug release kinetics from microemulsion-laden contact lenses.
    Maulvi FA; Desai AR; Choksi HH; Patil RJ; Ranch KM; Vyas BA; Shah DO
    Int J Pharm; 2017 May; 524(1-2):193-204. PubMed ID: 28366804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.
    Iyer GR; Cason MM; Womble SW; Li G; Chastain JE
    J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
    Kam KW; Chen LJ; Wat N; Young AL
    Ocul Immunol Inflamm; 2017 Oct; 25(5):663-677. PubMed ID: 27192186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
    Ayyappanavar S; Sridhar S; Kumar K; Jayanthi CR; Gangasagara SB; Rathod BLS; Preethi B; Mittal P
    Indian J Ophthalmol; 2021 Feb; 69(2):257-261. PubMed ID: 33463568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
    Aguilar AJ
    Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.
    Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F
    Expert Opin Pharmacother; 2017 Aug; 18(11):1137-1143. PubMed ID: 28656804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimization of a novel in situ gel for sustained ocular drug delivery using Box-Behnken design: In vitro, ex vivo, in vivo and human studies.
    Ranch KM; Maulvi FA; Naik MJ; Koli AR; Parikh RK; Shah DO
    Int J Pharm; 2019 Jan; 554():264-275. PubMed ID: 30423418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extended release of hyaluronic acid from hydrogel contact lenses for dry eye syndrome.
    Maulvi FA; Soni TG; Shah DO
    J Biomater Sci Polym Ed; 2015; 26(15):1035-50. PubMed ID: 26176811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. pH triggered controlled drug delivery from contact lenses: Addressing the challenges of drug leaching during sterilization and storage.
    Maulvi FA; Choksi HH; Desai AR; Patel AS; Ranch KM; Vyas BA; Shah DO
    Colloids Surf B Biointerfaces; 2017 Sep; 157():72-82. PubMed ID: 28577503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
    McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
    Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN; Luna JD; Discepola M
    Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained ophthalmic delivery of highly soluble drug using pH-triggered inner layer-embedded contact lens.
    Zhu Q; Cheng H; Huo Y; Mao S
    Int J Pharm; 2018 Jun; 544(1):100-111. PubMed ID: 29627356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.
    Abelson MB; Pratt S; Mussoline JE; Townsend D
    Clin Ther; 2003 Jul; 25(7):2070-84. PubMed ID: 12946551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
    Abelson MB
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.
    Scoper SV; Berdy GJ; Lichtenstein SJ; Rubin JM; Bloomenstein M; Prouty RE; Vogelson CT; Edwards MR; Waycaster C; Pasquine T; Gross RD; Robertson SM
    Adv Ther; 2007; 24(6):1221-32. PubMed ID: 18165204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.